BC Biomedical News

PSC 16 King Edward - Temporary Closure

Thursday, 27 November 2014 19:05

The King Edward Patient Service Centre will be closed on Monday, December 8, 2014, due to a BC Hydro Installation.

We would be pleased to serve you at an alternate location:
Oakridge - #33 – 5740 Cambie Street – open 7:30 am – 4 pm
City Square - #163 – 555 West 12th Avenue – open 7:30 am – 4 pm
Woodridge (LifeLabs) - #215 – 650 West 41st Avenue – open 6:30 am – 4:30 pm
Fairmont (LifeLabs) - #701 – 750 W. Broadway – open 7 am – 5 pm

King Edward PSC will re-open on Tuesday, December 9 – 7:30 am – 3:30 pm

 

Austin Avenue PSC Closure

Thursday, 23 October 2014 18:19

The Austin Avenue patient service centre will be closed on Saturday November 1st as this location changes to a LifeLabs Patient Service Centre. Our name will change, but our people will remain the same. Hours of Operation will remain the same. Effective Monday November 3rd, our normal hours of operation will resume. If you have any questions please contact Lifelabs at 604-507-5040.

 

Notice: Ebola and Community Laboratories

Monday, 20 October 2014 15:14

Please click here to find out more.
 

Becoming LifeLabs (September 2014)

Thursday, 11 September 2014 16:54

LifeLabs acquired BC Biomedical HealthCare in April 2013. Since then we have been working diligently to bring our organizations together to build a community laboratory that best meets the needs of patients and health care providers. By coming together under the LifeLabs name we will align our standardized processes and continue to deliver the highest standard of patient care, service, safety and quality.

Over the coming months, BC Biomedical Patient Service Centres will transition to LifeLabs collections centres. Initial transitions will take place on October 6 at Eagleridge in Coquitlam(located at 313-1194 Lansdowne Drive, Coquitlam, BC). This will be followed by transitions on November 3 at Austin, Coquitlam (located at 106-1015 Austin Avenue, Coquitlam, BC). Employees at these locations will remain the same and are committed to maintaining the high level of service you have come to expect.

We will be communicating these changes to health care providers and patients to make these transitions as smooth as possible. Should you have any questions about these changes, the LifeLabs Customer Care Centre is your first line of contact. Please call 1-800-431-7206 with any questions or concerns.

Thank you for your patience as we undergo this transition. We look forward to providing you with the same high quality lab services now and in the future.

 

PSC 36 Nelson Closure

Tuesday, 29 July 2014 19:35

Effective Friday, August 15, 2014, the Patient Service Centre at 206 – 6411 Nelson Avenue in Burnaby will be permanently closed. We will be pleased to continue serving you at these nearby locations:

#201 – 4980 Kingsway, Burnaby (BC Biomedical)
Monday – Friday 6:30 am – 6:00 pm
Saturday 7:00 am – 2:00 pm
Sunday 7:00 am – 12:00 pm

or

#302 – 3965 Kingsway, Burnaby (LifeLabs)
Monday – Friday 7:00 am – 5:00 pm
Saturday 7:00 am – 12:00 pm
Sunday Closed

 

Panorama™ NIPT now offers Microdeletion Screening

Tuesday, 20 May 2014 19:24

Panorama™ Non-Invasive Prenatal Test (NIPT) screens for common chromosome problems by analyzing fetal DNA in a maternal blood sample as early as 9 weeks in pregnancy. As of May 20th 2014, Panorama will offer the additional option to screen for five clinically relevant microdeletion syndromes that occur with a combined incidence of approximately 1 in every 1,000 births:


Panorama™ Prenatal test remains the most affordable NIPT in Canada, and expectant parents will now have 3 testing options:

  • The Panorama™ Prenatal test for detection of trisomy 21, 18, and 13, triploidy, and sex chromosome aneuploidies ($795) - gender is optional and available at no added cost
  • The Panorama™ Prenatal test ($795) + screening for 22q11.2 deletion syndrome($255)
  • The Panorama™ Prenatal Test ($795) + the Microdeletion Extended Panel* ($305)

    *Microdeletion Extended Panel screens for 22q11.2 deletion syndrome, Cri-du-chat syndrome, 1p36 deletion syndrome, Angelman syndrome, and Prader-Willi syndrome

For more information on microdeletions, view microdeletions patient pamphlet. You can reach us toll free at 1–84-GENEHELP (1-844-363-4357) or e-mail us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it


Panorama™ is:

  • Comprehensive – identifies trisomy 21, 18, 13, monosomy X, triploidy/vanishing twin and five clinically relevant microdeletion syndromes
  • Simple and safe – requires standard maternal blood draw
  • Timely – can be done as early as 9 weeks gestation
  • Accurate - >99% combined sensitivity for trisomy 21, 18, 13, monosomy X, triploidy (and <0.1% false positive rate)

Who is this test for?

Leading professional associations such as the American College of Obstetricians and Gynecologists (ACOG) and the Society of Obstetricians and Gynaecologists of Canada (SOGC) have recommended that NIPT be offered to women at increased risk of a fetal chromosome abnormality.


Indications of an increased risk include:

  • ≥35 years of age at delivery
  • an abnormal prenatal serum screen
  • personal history of a chromosome anomaly
  • history of a previous pregnancy with a trisomy
  • ultrasound finding suggestive of fetal aneuploidy

Although highly accurate, it is recommended that positive NIPT results be confirmed by diagnostic testing like amniocentesis or CVS.


When Should Panorama™ NOT be used:

  • twins or multiple gestations
  • egg donor or surrogate
  • previous bone marrow transplant

Ordering Panorama™ is easy:

  1. Physician completes and signs the Panorama™ laboratory requisition form and retains the signed patient consent form in the patient’s medical chart – BC requisition form | Consent Form
  2. Patients call LifeLabs at 1-855-412-4495 or BC Biomedical at 1-877-507-5595 to arrange for an appointment for a blood draw at a convenient location.
  3. Result sent to ordering physician within 10 days of blood draw (results may take up to 14 days for blood samples drawn on Fridays due to shipping restrictions on weekends).

Visit our Panorama™ NIPT page to learn more.

 

LifeLabs Medical Laboratory Services and Contextual Genomics Announce Co-Marketing and Testing Agreement

Monday, 21 April 2014 15:13

Toronto and Vancouver, April 16, 2014 – LifeLabs Medical Laboratory Services (“LifeLabs”) and Contextual Genomics announced today an agreement to co-market and offer tests for cancer and other genetic and genomic tests. This partnership reinforces LifeLabs’ leadership role in genetic testing across Canada and Contextual Genomics’ important role in molecular test development and interpretation. Genetic and genomic testing are the fastest growing segments in laboratory medicine and form the underlying basis for “personalized medicine”. With this partnership LifeLabs and Contextual Genomics have agreed to work together to bring genetic tests for cancer and other genetic-based conditions to physicians and patients across Canada.

“LifeLabs is committed to building a healthier Canada through the delivery of exceptional diagnostic testing, analysis, information and service. We are delighted to partner with Contextual Genomics, a Canadian company with extremely talented scientific leadership and unique medical informatics capabilities,” said Sue Paish, President and CEO of LifeLabs. “Genetic testing is a significant element of the future of health care. Together with Contextual Genomics, LifeLabs will help Canadians benefit from this growing and exciting area in an effective and efficient way.”

“Contextual Genomics delivers actionable information to patients and their caregivers based on a patient’s unique DNA blueprint. This information makes a difference in people’s lives,” said Chris Wagner, President and CEO of Contextual Genomics. “LifeLabs’ commitment to delivering innovative testing services to Canadians made them a natural partner for Contextual Genomics. Both companies share the same vision of delivering the highest quality testing and information to people regardless of where they live.”


About LifeLabs: www.LifeLabs.com
LifeLabs is a Canadian-owned company and is the country's largest provider of community laboratory services with over 50 years of experience providing laboratory testing services to help health care providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in health care. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, serving 19 million patients annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure.


About Borealis Infrastructure Management Inc.: www.borealis.ca
Borealis is a leader in direct infrastructure investing with over a decade of investment experience. Borealis manages approximately CAD 10 billion in OMERS equity capital through investments in a diversified portfolio of large-scale infrastructure assets exhibiting stability and strong cash flows, in sectors including energy, transportation and government regulated services. It has offices in Toronto, London and New York. Borealis is the infrastructure investment arm of OMERS, one of Canada’s largest pension funds with over CAD 65 billion in net assets.


About Contextual Genomics: www.contextualgenomics.com
Contextual Genomics believes that DNA analysis significantly improves human health and geography should not be a barrier to the benefits of using molecular information to guide patient decisions. The company’s first products are actionable molecular tests that guide diagnosis and treatment of cancer.



Contacts:
Chris Wagner
President and CEO
Contextual Genomics
604-484 4395
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Stephanie Sayer
Communications Manager
LifeLabs Medical Laboratory Services
416-675-4530 ext 2015
This e-mail address is being protected from spambots. You need JavaScript enabled to view it


This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

 

LifeLabs Medical Laboratory Services acquires Centogene’s Canadian Business

Thursday, 20 February 2014 16:58

TORONTO, February 19, 2014 – LifeLabs Medical Laboratory Services (“LifeLabs”) announced today the acquisition of Centogene AG’s (‘Centogene’) Canadian business. Based in Germany, Centogene is a world leader in genetics testing for inherited diseases, with not only one of the world’s most extensive genetic test portfolios, but also one of the largest databases of genetic mutations for rare diseases. Centogene performs testing for a number of genetic centres across Canada.

This acquisition places LifeLabs in a leadership role in genetic testing in Canada. Genetic and genomic testing are the fastest growing segments in laboratory medicine and form the underlying basis for ‘personalized medicine’. With this acquisition, all of Centogene’s testing services will continue uninterrupted for Centogene’s Canadian clients. Over the coming months, Centogene’s test portfolio will be transitioned from Germany to LifeLabs’ laboratories in Canada, resulting in an improved level of service and faster turn-around times for Canadians.

“LifeLabs is committed to building a healthier Canada through the delivery of exceptional diagnostic testing, information and service. We are thrilled to partner with Centogene, an established and respected world leader in genetic testing and medical interpretation with a deep understanding of the Canadian marketplace,” said Sue Paish, President and CEO of LifeLabs. “Genetic testing is a significant element of the future of health care in Canada. LifeLabs will work with Centogene, health care providers, patients and other stakeholders so that Canadians benefit from this growing and exciting area in an effective and efficient way.”

In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada.

“The purchase of Centogene’s Canadian business is another demonstration of the commitment that LifeLabs has to health care in Canada,” said John Knowlton, LifeLabs Board Chair. “With this purchase, LifeLabs will now have the ability to provide Canadians with a broad menu of high-quality genetic tests to serve their health care needs.”

“This partnership brings together LifeLabs’ Canadian presence, reputation and extensive network of sample collection centres throughout Canada with Centogene’s worldwide experience in genetic diagnostics and result interpretation, supported by our unique mutation database,” said Michael Schlenk, CEO of Centogene. “Working together, we will be able to serve patients and providers in the best possible way - especially since both our companies share the same commitment to patient care, quality and innovation.”


About LifeLabs

LifeLabs is a Canadian-owned company and is the country's largest provider of community laboratory services with over 50 years of experience providing laboratory testing services to help health care providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in health care. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, serving 19 million patients annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure. For more information, please visit: www.LifeLabs.com.


About Borealis Infrastructure Management Inc.

Borealis is a leader in direct infrastructure investing with over a decade of investment experience. Borealis manages approximately CAD 10 billion in OMERS equity capital through investments in a diversified portfolio of large-scale infrastructure assets exhibiting stability and strong cash flows, in sectors including energy, transportation and government-regulated services. It has offices in Toronto, London and New York. Borealis is the infrastructure investment arm of OMERS. For more information please visit: www.borealis.ca.


About OMERS

OMERS is one of Canada's largest pension funds with over $60 billion in net assets. It provides first-class pension administration and innovative products and services to over 430,000 members. Approximately one in every 20 employees working in the province of Ontario is an OMERS member. Through the OMERS Worldwide brand, our team of investment professionals uses a direct drive, active management investment strategy to invest in public and private market assets, including publicly-traded equities, fixed-income, infrastructure, private equity and real estate. For more information, please visit: www.omers.com or www.omersworldwide.com.


About CENTOGENE

CENTOGENE, founded in 2006, is a worldwide leader in the field of genetic diagnostics for rare hereditary diseases - with the largest test portfolio worldwide. Receiving samples from over 90 different countries allows Centogenea unique insight into epidemiological genetic differences, which is crucial in the medical result interpretation process.

The company is strictly focussing on offering quality molecular genetic diagnostics, underlined by our multiple international accreditations (ISO, CAP, CLIA).

Centogene's in depth medical expertise is supported by the application of cutting-edge technologies including next generation sequencing, whole exome sequencing (CentoXome®), whole genome sequencing and innovative biomarkers for selected diseases.

Centogene has developed a comprehensive mutation database (CentoMD®) that is pillar to offering high quality diagnostic reporting and medical interpretation, thoroughly interpret each patient's sequence data.

Beside diagnostic services for individual patients, Centogene is also a pivotal partner to multiple renown industrial partners worldwide.



Contact Information:

LifeLabs:
Stephanie Sayer
Communications Manager, LifeLabs
416-675-4530 ext 2015
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Centogene:
Michael Schlenk
CEO, Centogene
+49-162-1382411
This e-mail address is being protected from spambots. You need JavaScript enabled to view it


 

Effective February 1st, 2014, Panorama™ NIPT now includes Triploidy at no additional cost

Tuesday, 04 February 2014 18:34

Panorama™ Non-Invasive Prenatal Test (NIPT) screens for common chromosome problems like Down syndrome by analyzing fetal DNA in a maternal blood sample. The Society of Obstetricians and Gynaecologists of Canada (SOGC) has recommended that NIPT be offered to women at increased risk of a fetal chromosome problem.


Panorama™ is one of the most affordable NIPTs in Canada.

The cost is $795 for detection of trisomy 21, 18, 13, monosomy X, and tripoidy/vanishing twin (gender is optional and available at no added cost).

Panorama™ is the only NIPT that can detect triploidy, and this is now provided at no additional cost.


Panorama™ NIPT is:

  • Comprehensive - detection of trisomy 21, 18, 13, monosomy X, and triploidy/vanishing twin
  • Simple and safe - standard maternal blood draw
  • Timely - as early as 9 weeks gestation
  • Accurate - >99% sensitivity for trisomy 21, 18, and 13 (and <0.1% false positive rate)

Who Is This Test For?

Leading professional associations such as the American College of Obstetricians and Gynecologists (ACOG) and the Society of Obstetricians and Gynaecologists of Canada (SOGC) have recommended that NIPT be offered to women at increased risk of abnormal fetal chromosomal copy number.


Indications of an increased risk include:

  • ≥35 years of age at delivery
  • an abnormal prenatal serum screen
  • personal history of a chromosome anomaly
  • history of a previous pregnancy with a trisomy
  • ultrasound finding suggestive of fetal aneuploidy

Although highly accurate, it is recommended that positive NIPT results be confirmed by diagnostic testing like chorionic villus sampling or amniocentesis.


When Should Panorama™ NOT Be Used:

  • twins or multiple gestations
  • egg donor or surrogate
  • previous bone marrow transplant

Ordering Panorama™ is easy:

  • Physician completes and signs the Panorama™ laboratory requisition form and retains the signed patient consent form – BC Requisition Form | Consent Form
  • Patient calls LifeLabs at 1-855-412-4495 or BC Biomedical at 1-877-507-5595 to arrange an appointment for a blood draw at a convenient LifeLabs or BC Biomedical location
  • The result is sent to the ordering physician within 10 days of blood draw (Note: results may take up to 14 days when the blood sample is drawn on a Friday due to shipping restrictions on weekends).
  • LifeLabs will contact the ordering physician by telephone in the event of an abnormal result.

Visit our Panorama™ NIPT page to learn more.


 

New Standard Outpatient Laboratory Requisition

Tuesday, 12 November 2013 21:50

The Medical Services Commission has recently mandated changes to the Standard Outpatient Laboratory Requisition (SOPLR) specific to FIT testing. These changes can be found in the “Other Tests” section of the requisition.

To view an electronic copy of the requisition, please click here

To view a fillable printable copy, click here

 

LifeLabs Welcomes Naturopathic Doctors

Friday, 05 July 2013 22:42

LifeLabs and BC Biomedical are pleased to announce laboratory collection and testing services to Naturopathic Doctors of British Columbia.

Service Features

  • Over 100 Patient Service Locations across British Columbia. Some locations are open Saturday and Sunday for your patients’ convenience. Visit our LifeLabs and BC Biomedical websites to find the location closest to you.
  • Over 1000 routine and specialized tests.
  • Access to wellness, disease specific and gender tailored test panels.
  • Electronic reporting. Access test results electronically, most within 24 hours of the sample collection.
  • Kit collection service. We can help you facilitate sample collection for testing offered by out-of-country laboratory service providers.

To register for your account please complete the registration form.



Information Update – July 12, 2013

We have received an extraordinary amount of response to the announcement of our new service to Naturopathic Doctors. Thank you to all of you who expressed interest and submitted your registration form. We are currently processing a large number of applications so you may experience a small delay in having your account set up. We thank you for your patience.

In the meantime, here is some additional information that you may find useful.


Frequently Asked Questions

What is the Test Menu?
By registering for our service you will have access to our complete test menu. Please follow the links to the complete listing of our routine and specialized tests.

Are any of the tests billable to MSP?
No, the tests are not covered by the provincial medical service plan (MSP).

Could I see the price list before registering?
For confidentiality purposes, we are only able to share the fee schedule with our registered clients.

How is this service different from the arrangement with Rocky Mountain Analytical (RMA)?
RMA is a client of LifeLabs. The Naturopathic Doctors who submit RMA requisition forms will have their orders processed as per their signed service agreement with RMA. They will not be able to benefit from our faster turnaround time, free Excelleris electronic results reporting and competitive pricing. In order to have the tests processed under the LifeLabs service agreement, the clients will have to use LifeLabs requisition forms.

If I already order tests through LifeLabs, do I have to fill out a registration form?
Yes. Your account is with Rocky Mountain Analytical and in order to serve you directly, we need to have you register with us. Upon registration, you will be provided with separate requisition forms, electronic reporting information, and other elements unique to our service offering.

May I use both RMA and LifeLabs?
Yes, although you will likely find that going through LifeLabs directly will provide you with added service benefits.

If I am already a client of BC Biomedical, do I have to register again?
No. In April 2013, LifeLabs purchased BC Biomedical. Naturopathic Doctors who were BC Biomedical clients can now also use LifeLabs Patient Service Centers.

Please contact us by phone at 604-412-4421 should you require additional information.



LifeLabs Medical Laboratory Services Announces Agreement to Acquire CML HealthCare Inc.

Tuesday, 25 June 2013 17:49

TORONTO, June 25, 2013 – LifeLabs Medical Laboratory Services (“LifeLabs”), a leading Canadian provider of community laboratory services, announced today that it has entered into an Arrangement Agreement (the “Agreement”) with CML HealthCare Inc. (“CML”) under which LifeLabs will acquire all of the issued and outstanding common shares of CML for $10.75 per share in cash by way of a Plan of Arrangement.

The combination of LifeLabs with CML will expand community lab testing services for patients in the province of Ontario. LifeLabs and CML provide laboratory testing services that help Ontario health care providers diagnose, treat, monitor and prevent disease in patients. The two organizations provide high quality diagnostic services to community patients through patient service centers, homecare and long-term care facilities visits, and dedicated laboratory testing facilities. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure.

“I’m very pleased to announce that our two laboratory diagnostic companies are coming together in Ontario to serve patients and their health providers,” said Sue Paish, President and CEO of LifeLabs. “Coming together, we can be even stronger partners with government and health care providers in the planning and delivery of high quality and accessible diagnostic services for Canadians.”

“We see an exciting future for this business” said Michael Rolland, President and CEO of Borealis Infrastructure. “We welcome the talented staff at CML Healthcare to LifeLabs and look forward to the team working together to continue to lead the industry in the delivery of quality laboratory services that support the healthcare needs of Canadians.”

“Since 1971, CML has been a trusted partner of medical professionals, providing timely and accurate medical diagnostic testing services to Canadians,” said Patrice E. Merrin, Chairman of the CML Board of Directors. “LifeLabs, too, has an outstanding reputation of delivering quality care and I am confident that the combined organization will maintain and grow our trusted partner relationships. This is a natural fit for two strong companies.”

“Our two organizations care about patients and helping physicians identify the right course of action for better health care outcomes,” said Thomas Wellner, President and CEO of CML HealthCare. “So, in bringing the two companies together, we are fully aligned in our commitment to quality and continuous improvement in patient services in Ontario going forward. We are committed to transitioning seamlessly through our integration with LifeLabs, with a focus on operational excellence and providing the same level of quality service our customers and partners have come to expect.”

RBC Capital Markets is acting as financial advisor to Borealis Infrastructure and LifeLabs, and Blake, Cassels & Graydon LLP is acting as their legal advisor.

The Arrangement, which has been approved by the boards of directors of CML, LifeLabs and OMERS, is subject to approval by shareholders of CML at a Special Meeting to be held on September 3, 2013. The transaction is also subject to receipt of regulatory approvals and other customary closing conditions, including court approval. The transaction is expected to close in September of 2013.

About LifeLabs

LifeLabs is a Canadian-owned company and is the country’s largest provider of community laboratory services in the delivery of more than 50 million laboratory tests, serving over 11 million patients and 26,000 health care providers. For more information, visit: www.lifelabs.com.

For more information, please contact:

Mitchell Toker
Director Communications
Tel: 416-675-4530 X2880 / Cell: 416-885-0842
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

About Borealis Infrastructure Management Inc.

Borealis Infrastructure is a leader in direct infrastructure investing with over a decade of investment experience and almost $20 billion in capital under management. Borealis invests in and manages a diversified portfolio of large-scale infrastructure assets exhibiting stability and strong cash flows, in sectors including energy, transportation and government-regulated services. It has offices in Toronto, London and New York. Borealis is the infrastructure investment arm of the OMERS Worldwide group of companies. More information can be found on www.borealis.ca

About OMERS

OMERS is one of Canada's largest pension funds with over $60 billion in net assets. It provides first-class pension administration and innovative products and services to over 400,000 members. Approximately one in every 20 employees working in the province of Ontario is an OMERS member. Through the OMERS Worldwide brand, our team of investment professionals uses a direct drive, active management investment strategy to invest in public and private market assets, including publicly-traded equities, fixed-income, infrastructure, private equity and real estate. For more information, please visit www.omers.com or www.omersworldwide.com.

About CML

CML serves more than 6 million patients each year at its more than 200 lab and diagnostic imaging sites in Ontario and British Columbia, processing over 40 million tests annually. The Company has been providing laboratory diagnostic services for more than 40 years in Ontario and is a publicly traded company. For more information, visit: www.cmlhealthcare.com

 

Restricted 25-Hydroxy-Vitamin-D Testing as of June 1st

Saturday, 01 June 2013 00:00

As of June 1st, MSP will be making changes to their coverage of 25-Hydroxy-Vitamin-D testing.  After June 1st this test will be covered by MSP when ordered by a Specialist or for patients younger than 19 years of age. In all other scenarios, this test will be available at LifeLabs and BC Biomedical on a patient pay basis.

Read more: Restricted 25-Hydroxy-Vitamin-D Testing as of June 1st

Celebrates National Medical Laboratory Week

Wednesday, 24 April 2013 23:33

April 28 – May 4, 2013

 

National Medical Laboratory Week is an annual event that promotes awareness and understanding of the role of medical laboratory professionals in the health care system. Patient care is supported by medical laboratory professionals.

Click here to find out more

 

Page 1 of 4

«StartPrev1234NextEnd»

Hours of Operation

Looking for a list of our current hours of operation for all Patient Service Centres?

Click here to view a printable pdf

BC Bio Logo Best Employer in Canada green 30my ehealth

Information provided on this website is intended for Canadian residents and businesses only.
Copyright ©2002-2013. | Privacy Policy | CASL |Legal | Site Map | Contact